Intrinsic value of PerkinElmer - PKI

Previous Close

$75.50

  Intrinsic Value

$40.37

stock screener

  Rating & Target

sell

-47%

Previous close

$75.50

 
Intrinsic value

$40.37

 
Up/down potential

-47%

 
Rating

sell

We calculate the intrinsic value of PKI stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2017(a)
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  0.52
  6.70
  6.53
  6.38
  6.24
  6.12
  6.00
  5.90
  5.81
  5.73
  5.66
  5.59
  5.53
  5.48
  5.43
  5.39
  5.35
  5.32
  5.28
  5.26
  5.23
  5.21
  5.19
  5.17
  5.15
  5.14
  5.12
  5.11
  5.10
  5.09
  5.08
Revenue, $m
  2,116
  2,408
  2,565
  2,729
  2,899
  3,077
  3,261
  3,454
  3,655
  3,864
  4,083
  4,311
  4,550
  4,799
  5,060
  5,332
  5,618
  5,916
  6,229
  6,556
  6,899
  7,258
  7,635
  8,029
  8,443
  8,876
  9,331
  9,808
  10,308
  10,832
  11,383
Variable operating expenses, $m
 
  2,008
  2,111
  2,218
  2,329
  2,445
  2,566
  2,691
  2,823
  2,959
  3,102
  2,817
  2,972
  3,135
  3,306
  3,484
  3,670
  3,865
  4,069
  4,283
  4,507
  4,742
  4,988
  5,246
  5,516
  5,799
  6,096
  6,408
  6,734
  7,077
  7,436
Fixed operating expenses, $m
 
  44
  45
  46
  47
  48
  49
  50
  51
  52
  53
  55
  56
  57
  58
  60
  61
  62
  64
  65
  66
  68
  69
  71
  72
  74
  76
  77
  79
  81
  83
Total operating expenses, $m
  1,832
  2,052
  2,156
  2,264
  2,376
  2,493
  2,615
  2,741
  2,874
  3,011
  3,155
  2,872
  3,028
  3,192
  3,364
  3,544
  3,731
  3,927
  4,133
  4,348
  4,573
  4,810
  5,057
  5,317
  5,588
  5,873
  6,172
  6,485
  6,813
  7,158
  7,519
Operating income, $m
  283
  356
  410
  465
  523
  584
  647
  712
  781
  852
  927
  1,440
  1,522
  1,607
  1,696
  1,789
  1,887
  1,989
  2,096
  2,208
  2,325
  2,448
  2,577
  2,713
  2,855
  3,003
  3,159
  3,323
  3,495
  3,675
  3,864
EBITDA, $m
  383
  1,189
  1,269
  1,351
  1,438
  1,527
  1,621
  1,718
  1,820
  1,926
  2,037
  2,153
  2,274
  2,400
  2,532
  2,671
  2,815
  2,967
  3,125
  3,292
  3,466
  3,648
  3,839
  4,040
  4,250
  4,471
  4,702
  4,944
  5,198
  5,465
  5,745
Interest expense (income), $m
  31
  108
  121
  134
  149
  163
  178
  194
  211
  228
  246
  265
  284
  305
  326
  348
  372
  396
  422
  449
  477
  506
  537
  569
  603
  638
  676
  715
  755
  798
  843
Earnings before tax, $m
  244
  248
  289
  331
  375
  421
  468
  518
  570
  625
  681
  1,175
  1,237
  1,302
  1,370
  1,441
  1,515
  1,593
  1,674
  1,759
  1,849
  1,942
  2,041
  2,144
  2,252
  2,365
  2,484
  2,608
  2,739
  2,876
  3,020
Tax expense, $m
  28
  67
  78
  89
  101
  114
  126
  140
  154
  169
  184
  317
  334
  352
  370
  389
  409
  430
  452
  475
  499
  524
  551
  579
  608
  639
  671
  704
  740
  777
  816
Net income, $m
  234
  181
  211
  242
  274
  307
  342
  378
  416
  456
  497
  858
  903
  951
  1,000
  1,052
  1,106
  1,163
  1,222
  1,284
  1,350
  1,418
  1,490
  1,565
  1,644
  1,726
  1,813
  1,904
  2,000
  2,100
  2,205

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  359
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  4,277
  6,491
  6,915
  7,356
  7,815
  8,293
  8,791
  9,310
  9,851
  10,416
  11,005
  11,620
  12,263
  12,935
  13,638
  14,373
  15,142
  15,947
  16,789
  17,672
  18,596
  19,564
  20,579
  21,642
  22,757
  23,925
  25,151
  26,436
  27,784
  29,198
  30,681
Adjusted assets (=assets-cash), $m
  3,918
  6,491
  6,915
  7,356
  7,815
  8,293
  8,791
  9,310
  9,851
  10,416
  11,005
  11,620
  12,263
  12,935
  13,638
  14,373
  15,142
  15,947
  16,789
  17,672
  18,596
  19,564
  20,579
  21,642
  22,757
  23,925
  25,151
  26,436
  27,784
  29,198
  30,681
Revenue / Adjusted assets
  0.540
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
  0.371
Average production assets, $m
  595
  3,981
  4,241
  4,511
  4,793
  5,086
  5,391
  5,709
  6,041
  6,387
  6,749
  7,126
  7,521
  7,933
  8,364
  8,814
  9,286
  9,780
  10,296
  10,837
  11,404
  11,998
  12,620
  13,272
  13,956
  14,673
  15,424
  16,212
  17,039
  17,906
  18,816
Working capital, $m
  587
  137
  146
  156
  165
  175
  186
  197
  208
  220
  233
  246
  259
  274
  288
  304
  320
  337
  355
  374
  393
  414
  435
  458
  481
  506
  532
  559
  588
  617
  649
Total debt, $m
  1,046
  2,241
  2,491
  2,750
  3,021
  3,302
  3,595
  3,901
  4,220
  4,552
  4,900
  5,262
  5,641
  6,037
  6,451
  6,883
  7,336
  7,810
  8,307
  8,826
  9,371
  9,941
  10,538
  11,165
  11,821
  12,510
  13,232
  13,989
  14,782
  15,615
  16,489
Total liabilities, $m
  2,123
  3,823
  4,073
  4,333
  4,603
  4,885
  5,178
  5,483
  5,802
  6,135
  6,482
  6,844
  7,223
  7,619
  8,033
  8,466
  8,919
  9,393
  9,889
  10,409
  10,953
  11,523
  12,121
  12,747
  13,404
  14,092
  14,814
  15,571
  16,365
  17,198
  18,071
Total equity, $m
  2,154
  2,668
  2,842
  3,023
  3,212
  3,408
  3,613
  3,826
  4,049
  4,281
  4,523
  4,776
  5,040
  5,316
  5,605
  5,907
  6,223
  6,554
  6,900
  7,263
  7,643
  8,041
  8,458
  8,895
  9,353
  9,833
  10,337
  10,865
  11,419
  12,000
  12,610
Total liabilities and equity, $m
  4,277
  6,491
  6,915
  7,356
  7,815
  8,293
  8,791
  9,309
  9,851
  10,416
  11,005
  11,620
  12,263
  12,935
  13,638
  14,373
  15,142
  15,947
  16,789
  17,672
  18,596
  19,564
  20,579
  21,642
  22,757
  23,925
  25,151
  26,436
  27,784
  29,198
  30,681
Debt-to-equity ratio
  0.486
  0.840
  0.880
  0.910
  0.940
  0.970
  1.000
  1.020
  1.040
  1.060
  1.080
  1.100
  1.120
  1.140
  1.150
  1.170
  1.180
  1.190
  1.200
  1.220
  1.230
  1.240
  1.250
  1.260
  1.260
  1.270
  1.280
  1.290
  1.290
  1.300
  1.310
Adjusted equity ratio
  0.458
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  234
  181
  211
  242
  274
  307
  342
  378
  416
  456
  497
  858
  903
  951
  1,000
  1,052
  1,106
  1,163
  1,222
  1,284
  1,350
  1,418
  1,490
  1,565
  1,644
  1,726
  1,813
  1,904
  2,000
  2,100
  2,205
Depreciation, amort., depletion, $m
  100
  833
  859
  886
  914
  943
  974
  1,006
  1,039
  1,074
  1,110
  713
  752
  793
  836
  881
  929
  978
  1,030
  1,084
  1,140
  1,200
  1,262
  1,327
  1,396
  1,467
  1,542
  1,621
  1,704
  1,791
  1,882
Funds from operations, $m
  316
  1,014
  1,070
  1,128
  1,188
  1,251
  1,316
  1,384
  1,455
  1,530
  1,607
  1,571
  1,655
  1,744
  1,836
  1,933
  2,035
  2,141
  2,252
  2,368
  2,490
  2,618
  2,752
  2,892
  3,039
  3,194
  3,356
  3,525
  3,703
  3,890
  4,087
Change in working capital, $m
  -35
  9
  9
  9
  10
  10
  11
  11
  11
  12
  12
  13
  14
  14
  15
  16
  16
  17
  18
  19
  20
  20
  21
  22
  24
  25
  26
  27
  29
  30
  31
Cash from operations, $m
  351
  1,005
  1,061
  1,118
  1,178
  1,240
  1,305
  1,373
  1,444
  1,518
  1,595
  1,558
  1,642
  1,730
  1,822
  1,918
  2,018
  2,124
  2,234
  2,349
  2,470
  2,597
  2,730
  2,870
  3,016
  3,169
  3,330
  3,498
  3,675
  3,860
  4,055
Maintenance CAPEX, $m
  0
  -373
  -398
  -424
  -451
  -479
  -509
  -539
  -571
  -604
  -639
  -675
  -713
  -752
  -793
  -836
  -881
  -929
  -978
  -1,030
  -1,084
  -1,140
  -1,200
  -1,262
  -1,327
  -1,396
  -1,467
  -1,542
  -1,621
  -1,704
  -1,791
New CAPEX, $m
  -32
  -250
  -260
  -270
  -281
  -293
  -305
  -318
  -332
  -346
  -361
  -377
  -394
  -412
  -431
  -451
  -472
  -494
  -517
  -541
  -567
  -594
  -622
  -652
  -684
  -717
  -752
  -788
  -827
  -867
  -910
Cash from investing activities, $m
  -101
  -623
  -658
  -694
  -732
  -772
  -814
  -857
  -903
  -950
  -1,000
  -1,052
  -1,107
  -1,164
  -1,224
  -1,287
  -1,353
  -1,423
  -1,495
  -1,571
  -1,651
  -1,734
  -1,822
  -1,914
  -2,011
  -2,113
  -2,219
  -2,330
  -2,448
  -2,571
  -2,701
Free cash flow, $m
  250
  382
  403
  424
  446
  468
  492
  516
  541
  567
  594
  505
  535
  565
  597
  631
  665
  701
  739
  779
  820
  863
  908
  955
  1,005
  1,057
  1,111
  1,168
  1,227
  1,289
  1,355
Issuance/(repayment) of debt, $m
  63
  235
  250
  260
  270
  281
  293
  306
  319
  333
  347
  363
  379
  396
  414
  433
  453
  474
  496
  520
  544
  570
  598
  626
  657
  688
  722
  757
  794
  833
  874
Issuance/(repurchase) of shares, $m
  -137
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -84
  235
  250
  260
  270
  281
  293
  306
  319
  333
  347
  363
  379
  396
  414
  433
  453
  474
  496
  520
  544
  570
  598
  626
  657
  688
  722
  757
  794
  833
  874
Total cash flow (excl. dividends), $m
  152
  617
  652
  683
  716
  750
  785
  822
  860
  900
  942
  868
  914
  961
  1,011
  1,063
  1,118
  1,175
  1,236
  1,298
  1,364
  1,433
  1,506
  1,582
  1,661
  1,745
  1,833
  1,925
  2,021
  2,122
  2,229
Retained Cash Flow (-), $m
  -44
  -165
  -174
  -181
  -189
  -196
  -205
  -213
  -222
  -232
  -242
  -253
  -264
  -276
  -289
  -302
  -316
  -331
  -346
  -363
  -380
  -398
  -417
  -437
  -458
  -480
  -504
  -528
  -554
  -581
  -610
Prev. year cash balance distribution, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  25
  26
  28
  30
  32
  34
  36
  38
  40
  43
  45
  47
  50
  53
  56
  59
  62
  65
  69
  72
  76
  80
  84
  88
  93
  98
  103
  108
  113
  119
Cash available for distribution, $m
 
  452
  478
  502
  527
  553
  580
  608
  637
  668
  699
  615
  649
  685
  722
  761
  802
  845
  889
  936
  984
  1,035
  1,089
  1,145
  1,203
  1,265
  1,329
  1,396
  1,467
  1,541
  1,619
Discount rate, %
 
  7.40
  7.77
  8.16
  8.57
  8.99
  9.44
  9.92
  10.41
  10.93
  11.48
  12.05
  12.66
  13.29
  13.95
  14.65
  15.38
  16.15
  16.96
  17.81
  18.70
  19.63
  20.62
  21.65
  22.73
  23.87
  25.06
  26.31
  27.63
  29.01
  30.46
PV of cash for distribution, $m
 
  421
  412
  397
  379
  360
  338
  314
  289
  262
  236
  176
  155
  135
  116
  98
  81
  66
  53
  42
  32
  24
  18
  13
  9
  6
  4
  3
  2
  1
  1
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

PerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets. It provides analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, lubricant, petrochemical and polymer industries. Its products include AAnalyst, Altus, Aquamatic, Avio, AxION, Clarus, DairyGuard, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, Cell carrier and cell::explorer. The Diagnostics segment is focused on reproductive health, emerging market diagnostics and applied genomics. Its products include AutoDELFIA, BACS-on-Beads, Bioo Scientific, BoBs, Datalytix, Dexela, Dexela CMOS FPDs, Evolution, ViaCord, and Zephyr.

FINANCIAL RATIOS  of  PerkinElmer (PKI)

Valuation Ratios
P/E Ratio 35.4
Price to Sales 3.9
Price to Book 3.8
Price to Tangible Book
Price to Cash Flow 23.6
Price to Free Cash Flow 25.9
Growth Rates
Sales Growth Rate 0.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 14.3%
Cap. Spend. - 3 Yr. Gr. Rate -3.9%
Financial Strength
Quick Ratio 359
Current Ratio 0.3
LT Debt to Equity 48.5%
Total Debt to Equity 48.6%
Interest Coverage 9
Management Effectiveness
Return On Assets 6.2%
Ret/ On Assets - 3 Yr. Avg. 5.5%
Return On Total Capital 7.4%
Ret/ On T. Cap. - 3 Yr. Avg. 6.5%
Return On Equity 11%
Return On Equity - 3 Yr. Avg. 9.7%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 47.9%
Gross Margin - 3 Yr. Avg. 46.2%
EBITDA Margin 17.7%
EBITDA Margin - 3 Yr. Avg. 16%
Operating Margin 13.4%
Oper. Margin - 3 Yr. Avg. 11.6%
Pre-Tax Margin 11.5%
Pre-Tax Margin - 3 Yr. Avg. 9.7%
Net Profit Margin 11.1%
Net Profit Margin - 3 Yr. Avg. 9.4%
Effective Tax Rate 11.5%
Eff/ Tax Rate - 3 Yr. Avg. 8.8%
Payout Ratio 13.2%

PKI stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the PKI stock intrinsic value calculation we used $2257 million for the last fiscal year's total revenue generated by PerkinElmer. The default revenue input number comes from 2017 income statement of PerkinElmer. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our PKI stock valuation model: a) initial revenue growth rate of 6.7% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 7.4%, whose default value for PKI is calculated based on our internal credit rating of PerkinElmer, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of PerkinElmer.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of PKI stock the variable cost ratio is equal to 84.6%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $43 million in the base year in the intrinsic value calculation for PKI stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for PerkinElmer.

Corporate tax rate of 27% is the nominal tax rate for PerkinElmer. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the PKI stock is equal to 1.1%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for PKI are equal to 165.3%.

Life of production assets of 10 years is the average useful life of capital assets used in PerkinElmer operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for PKI is equal to 5.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $2503 million for PerkinElmer - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 110 million for PerkinElmer is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of PerkinElmer at the current share price and the inputted number of shares is $8.3 billion.

RELATED COMPANIES Price Int.Val. Rating
TMO Thermo Fisher 208.80 95.38  str.sell
HBIO Harvard Biosci 5.15 0.17  str.sell
BRKR Bruker 28.41 25.54  hold
WAT Waters 193.50 69.51  str.sell
A Agilent Techno 62.72 67.60  hold
BIO Bio-Rad Labora 300.52 51.35  str.sell
MTD Mettler-Toledo 575.36 365.91  sell

COMPANY NEWS

▶ Should You Buy PerkinElmer Inc (NYSE:PKI) Now?   [Jun-21-18 08:01AM  Simply Wall St.]
▶ PerkinElmer: 1Q Earnings Snapshot   [04:25PM  Associated Press]
▶ PerkinElmer, Inc. to Host Earnings Call   [01:00PM  ACCESSWIRE]
▶ PerkinElmer Board Declares Quarterly Dividend   [Apr-26-18 04:15PM  Business Wire]
▶ PerkinElmer Appoints James Mock as Chief Financial Officer   [Apr-10-18 04:30PM  Business Wire]
▶ PerkinElmer to Hold Earnings Call on Monday, April 30, 2018   [Apr-06-18 04:34PM  Business Wire]
▶ PerkinElmer to Acquire RHS for $0.28/Share   [Feb-25-18 05:47PM  Benzinga]
Financial statements of PKI
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.